Operationalizing Treatment with Bispecifics for Multiple Myeloma

Experts discuss the impact of advances in the treatment of multiple myeloma on patient care.

Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.

Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.

Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.

Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.

Experts discuss their institution’s implementation of step-up dosing for bispecific antibodies and share their best practices.

Experts discuss challenges related to the implementation of bispecific antibodies for the treatment of multiple myeloma and emphasize the critical role of interinstitutional collaboration in developing bispecific antibody programs.

Panelists provide concluding perspectives on the operationalization of bispecific antibodies for multiple myeloma.

Michael Singel, PharmD; and Carol Ann Huff, MD, discuss how step-up dosing for bispecific antibodies has been implemented in the outpatient setting with monitoring considerations for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome to ensure patient safety.

Carol Ann Huff, MD, describes her institution's multidisciplinary approach to monitoring for adverse events when administering bispecific antibodies, including the roles of nurses, pharmacists, and attending physicians.

Michael Singel, PharmD, discusses the logistics of complying with the Risk Evaluation and Mitigation Strategy program for bispecific antibodies at his institution and addresses training and documentation requirements.

Michael Singel, PharmD, discusses the role of pharmacists in the operationalization of bispecifics to treat multiple myeloma, including the creation of treatment plans and standard of care order sets.

Medical experts describe unmet needs in the treatment of patients with multiple myeloma, describing challenges related to access to care and extramedullary disease.

Carol Ann Huff, MD discusses how the approval of additional bispecific antibodies for multiple myeloma might change the treatment selection process, highlighting considerations for sequencing of agents and combination therapy.

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.

Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.

Medical professionals share insights on treatment considerations and patient selection for bispecific antibody therapy and the process for referring patients to other institutions for care.

The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.

Key opinion leaders address the importance of coordination between academic hospital providers and community oncologists when transitioning from initiation of bispecific antibodies at a tertiary hospital to maintenance therapy in the community oncology setting.

Sarah Rockwell, PharmD, BCOP, explores how community oncology practices can understand and meet the requirements of risk evaluation and mitigation strategy programs, and stresses the importance of developing and implementing standard operating procedures.

Medical professionals highlight the essential support provided by pharmacists in addressing operational challenges related to bispecific antibodies. Pharmacists can play an important role in the development of policies and procedures, monitoring and management of toxicities, and delivery of educational resources.

Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.

Sarah Rockwell, PharmD, BCOP, and Ke Ning, MD, share their concluding remarks, reflecting on the current landscape and expressing their aspirations for addressing remaining unmet needs.